Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB Therapeutics_resized
IRLAB Therapeutics (OMX: IRLAB-A) misses primary endpoint with pirepemat
Published by Jyoti Prakash, CFA

IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its second most clinically advanced asset, pirepemat, as a potential treatment for falls related to Parkinson’s disease (PF-Falls), a common comorbidity to the condition. The company has noted that, while the high-dose arm (600mg daily) reported a 42% reduction in falls over the 12-week study duration, the results were not statistically significant over the placebo arm. Moreover, while the high-dose arm indicated a meaningful improvement in cognitive impairment on the Montreal Cognitive Assessment scale, these results were also not statistically significant.

Management will now conduct an in-depth analysis of the study data and, while we await further details of the results, we expect, at the least, a significant impact on the development timelines for the asset. The stock is trading down 51% at the time of writing.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.